Sponsors (7)
The bill reduces direct-to-consumer drug advertising—likely cutting misleading promotion, clinician pressure, and some marketing-driven spending—while risking reduced public awareness of new therapies, lost sponsor-to-consumer communication, a shift of promotion to other channels, and added legal/compliance costs.
Patients—especially those with chronic conditions—will have reduced exposure to direct-to-consumer drug advertising, decreasing exposure to potentially misleading or confusing promotional claims.
Clinicians and hospitals will face less pressure from patient requests for heavily marketed brand drugs, supporting more evidence-based prescribing and reducing time spent managing advertising-driven demands.
Patients and taxpayers could see modest reductions in marketing-driven drug spending, which may help slow price inflation tied to heavy consumer promotion.
Patients—particularly those seeking new or specialized therapies—will lose a direct channel for learning about new drugs and indications, which may reduce awareness and slow uptake of clinically beneficial treatments.
Holders of NDAs/BLAs (drug sponsors) will lose a major consumer-facing channel to communicate benefits, risks, and availability of their products, complicating patient outreach and informed decision-making.
Pharmaceutical companies may shift promotional efforts toward healthcare providers or alternative marketing channels, increasing pressure on clinicians and potentially raising overall industry marketing expenditures.
Based on analysis of 2 sections of legislative text.
Prohibits direct-to-consumer advertising for prescription drugs across TV, radio, print, digital and social media for all approved or licensed drugs.
Introduced June 12, 2025 by Bernard Sanders · Last progress June 12, 2025
Bans direct-to-consumer advertising of prescription drugs across TV, radio, print, digital platforms, and social media. The ban applies to drugs approved or licensed under federal law and takes effect 30 days after enactment, covering drugs approved or licensed at any time. The bill adds a new prohibition to the Federal Food, Drug, and Cosmetic Act that defines “direct-to-consumer advertising” and makes that advertising unlawful for covered prescription drugs, with applicability tied to whether the drug’s application holder or licensee has conducted consumer-targeted promotion within the prior 30 days.